Update on Teva Pharmaceuticals ($TEVA): Still a value opportunity while the company is rebuilding

Background

After years of underperformance and litigation overhang, Teva is turning a corner. In my view, the company is still mis-priced, trading at a deeply discounted valuation approximately 5.8x 2025 EPS estimate, the market is largely still overlooking the structural improvements the company is undergoing. With a clear cost optimization roadmap, a r…